Fibroid growth and medical options for treatment

被引:56
作者
Chabbert-Buffet, Nathalie [1 ]
Esber, Nathalie [2 ,3 ]
Bouchard, Philippe [4 ,5 ]
机构
[1] Hosp Tenon, AP HP, Obstet Gynecol & Reprod Med Dept, Paris, France
[2] INSERM, U693, Le Kremlin Bicetre, France
[3] Fac Med Paris Sud, Le Kremlin Bicetre, France
[4] Univ Paris Sud, UMR S693, Le Kremlin Bicetre, France
[5] Univ Paris 06, Paris, France
关键词
Fibroids; sex steroids; fibroids treatment; progestins; selective progesterone receptor modulators; selective estrogen receptor modulators; PROGESTERONE-RECEPTOR MODULATOR; HUMAN UTERINE LEIOMYOMA; CATECHOL-O-METHYLTRANSFERASE; LOW-DOSE MIFEPRISTONE; EXTRACELLULAR-MATRIX; ESTROGEN-RECEPTOR; VITAMIN-D; PERIMENOPAUSAL WOMEN; INTRAUTERINE SYSTEM; ULIPRISTAL ACETATE;
D O I
10.1016/j.fertnstert.2014.07.1238
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Although fibroids are common benign tumors, their impact on women's quality of life can be considerable. The most frequent symptoms are uterine bleeding, resulting in anemia, and pelvic pain. Fibroids can be of genetic or hormonal origin or arise from intrauterine events. Current options for medical treatment include control of estradiol and progesterone production or action and are discussed in this review. Although curative treatment of fibroids relies on surgical strategies, the current trend is for uterine-sparing treatment to preserve fertility and avoid unnecessary surgery. Currently approved medical treatments include intrauterine progestin delivery to reduce uterine bleeding, GnRH analogues, and, more recently, selective progesterone receptor modulators to control uterine bleeding and reduce fibroid volume. (C) 2014 by American Society for Reproductive Medicine.
引用
收藏
页码:630 / 639
页数:10
相关论文
共 151 条
[1]
Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer [J].
Alam, NA ;
Olpin, S ;
Leigh, IM .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (01) :11-17
[2]
[Anonymous], 2005, Drug News Perspect, V18, P404
[3]
Progesterone receptor A and B isoforms in the human breast and its disorders [J].
Ariga, N ;
Suzuki, T ;
Moriya, T ;
Kimura, M ;
Inoue, T ;
Ohuchi, N ;
Sasano, H .
JAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (03) :302-308
[4]
Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium [J].
Arnett-Mansfield, RL ;
deFazio, A ;
Mote, PA ;
Clarke, CL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (03) :1429-1442
[5]
Pathogenesis of Benign Metastasizing Leiomyoma A Review [J].
Awonuga, Awoniyi O. ;
Shavell, Valerie I. ;
Imudia, Anthony N. ;
Rotas, Michael ;
Diamond, Michael P. ;
Puscheck, Elizabeth E. .
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2010, 65 (03) :189-195
[6]
Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development [J].
Baird, DD ;
Newbold, R .
REPRODUCTIVE TOXICOLOGY, 2005, 20 (01) :81-84
[7]
Vitamin D and the Risk of Uterine Fibroids [J].
Baird, Donna Day ;
Hill, Michael C. ;
Schectman, Joel M. ;
Hollis, Bruce W. .
EPIDEMIOLOGY, 2013, 24 (03) :447-453
[8]
Estrogen receptor a and β in uterine fibroids: a basis for altered estrogen responsiveness [J].
Bakas, Panagiotis ;
Liapis, Angelos ;
Vlahopoulos, Spiros ;
Giner, Maria ;
Logotheti, Stella ;
Creatsas, Georgios ;
Meligova, Aggeliki K. ;
Alexis, Michael N. ;
Zoumpourlis, Vassilis .
FERTILITY AND STERILITY, 2008, 90 (05) :1878-1885
[9]
Vitamin D inhibits myometrial and leiomyoma cell proliferation in vitro [J].
Blauer, Merja ;
Rovio, Paivi H. ;
Ylikomi, Timo ;
Heinonen, Pentti K. .
FERTILITY AND STERILITY, 2009, 91 (05) :1919-1925
[10]
Current and future medical treatments for menometrorrhagia during the premenopause [J].
Bouchard, Philippe .
GYNECOLOGICAL ENDOCRINOLOGY, 2011, 27 :1120-1125